Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth
Astria Therapeutics' Potential Hereditary Angioedema Treatment Gets FDA Orphan Drug Designation
Express News | Astria Therapeutics: To Share Additional Results From Alpha-Star Trial in Q4 & to Progress Navenibart Into Phase 3 Trial Initiating in Q1 2025
Express News | Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (Star-0215) for the Treatment of Hereditary Angioedema
Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema
H.C. Wainwright Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $16
Evercore Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $25
TD Cowen Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $35
Astria Therapeutics Down Over 15%, on Pace for Largest Percent Decrease Since June 2022 -- Data Talk
Astria Therapeutics To Present Initial Navenibart ALPHA-STAR Data At The Upcoming European Academy Of Dermatology And Venereology Congress
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Astria Therapeutics to Present at Upcoming Bradykinin Symposium
Astria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare Conference
Evercore Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Raises Target Price to $25
Evercore analyst Liisa Bayko maintains $Astria Therapeutics Inc(ATXS.US)$ with a buy rating, and adjusts the target price from $18 to $25.According to TipRanks data, the analyst has a success rate
A Quick Look at Today's Ratings for Astria Therapeutics Inc(ATXS.US), With a Forecast Between $16 to $35
On Aug 13, major Wall Street analysts update their ratings for $Astria Therapeutics Inc(ATXS.US)$, with price targets ranging from $16 to $35.TD Cowen analyst Stacy Ku maintains with a buy rating,
Astria Therapeutics Price Target Maintained With a $22.00/Share by Wedbush
Astria Therapeutics Is Maintained at Outperform by Oppenheimer
Express News | Astria Therapeutics : Oppenheimer Raises Target Price to $26 From $25